These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37782932)

  • 1. In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA
    Belal H; Gandhi GY
    Ann Intern Med; 2023 Oct; 176(10):JC113. PubMed ID: 37782932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA
    Belal H; Gandhi GY
    Ann Intern Med; 2023 Aug; 176(8):JC94. PubMed ID: 37523705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA
    Griffin TP; Dinneen SF
    Ann Intern Med; 2021 Mar; 174(3):JC34. PubMed ID: 33646841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
    Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
    N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In T2DM uncontrolled with noninsulin glucose-lowering agents, weekly icodec reduced HbA
    Belal H; Gandhi GY
    Ann Intern Med; 2023 Oct; 176(10):JC112. PubMed ID: 37782923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.
    Bajaj HS; Ásbjörnsdóttir B; Carstensen L; Laugesen C; Mathieu C; Philis-Tsimikas A; Battelino T
    Diabetes Care; 2024 Apr; 47(4):729-738. PubMed ID: 38380954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
    Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-Weekly Insulin Icodec
    Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK
    Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Sep; 16(9):102615. PubMed ID: 36108418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
    Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.
    Bajaj HS; Aberle J; Davies M; Donatsky AM; Frederiksen M; Yavuz DG; Gowda A; Lingvay I; Bode B
    Ann Intern Med; 2023 Nov; 176(11):1476-1485. PubMed ID: 37748181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4.
    Betônico CC; Titan SMO; Lira A; Pelaes TS; Correa-Giannella MLC; Nery M; Queiroz M
    Clin Ther; 2019 Oct; 41(10):2008-2020.e3. PubMed ID: 31383366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In T2DM requiring insulin initiation, icodec titrated with an app safely reduced HbA
    Liakos A; Karagiannis T; Tsapas A
    Ann Intern Med; 2024 Jan; 177(1):JC6. PubMed ID: 38163368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
    Philis-Tsimikas A; Bajaj HS; Begtrup K; Cailleteau R; Gowda A; Lingvay I; Mathieu C; Russell-Jones D; Rosenstock J
    Diabetes Obes Metab; 2023 Feb; 25(2):331-341. PubMed ID: 36106652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Misbin RI
    N Engl J Med; 2023 Oct; 389(16):1532-1533. PubMed ID: 37851883
    [No Abstract]   [Full Text] [Related]  

  • 19. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Sugiyama K
    N Engl J Med; 2023 Oct; 389(16):1532. PubMed ID: 37851882
    [No Abstract]   [Full Text] [Related]  

  • 20. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.